A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

作者：Atmaca A^*; Al Batran S E; Werner D; Pauligk C; Guener T; Koepke A; Bernhard H; Wenzel T; Banat A G; Brueck P; Caca K; Prasnikar N; Kullmann F; Derigs H Guenther; Koenigsmann M; Dingeldein G; Neuhaus T; Jaeger E

来源：British Journal of Cancer, 2013, 108(2): 265-270.

DOI：10.1038/bjc.2012.555

• chemotherapy
• cisplatin
• docetaxel
• oxaliplatin
• NSCLC
• metastatic

Background: This study was designed to compare cisplatin/docetaxel with oxaliplatin/docetaxel in patients with advanced and metastatic non-small lung cancer as a first-line treatment.
Methods: Patients were randomly assigned to receive either cisplatin 75 mg m(-2) and docetaxel 75 mg m(-2) every 3 weeks or oxaliplatin 85 mg m(-2) and docetaxel 50 mg m(-2) every 2 weeks. The primary end point was response rate, and secondary end points were toxicity, time to progression and overall survival.
Results: A total of 88 patients (median age: 65 (39-86) years; stage IV: 93%) were randomly assigned. Response rate (complete and partial response) was 47% (95% CI: 33-61%) in the cisplatin/docetaxel arm and 28% (95% CI: 17-43%) in the oxaliplatin/docetaxel arm (P = 0.118). There was no significant difference in time to progression (6.3 vs 4.9 months, P = 0.111) and median overall survival (11.6 vs 7.0 months, P = 0.102) with cisplatin/docetaxel vs oxaliplatin/docetaxel, although slight trends favouring cisplatin were seen. Oxaliplatin/docetaxel was associated with significantly less (any grade) renal toxicity (56% vs 11%), any grade fatigue (81% vs 59%), complete alopecia (76% vs 27%), any grade leukopenia (84% vs 61%) and grade 3/4 leukopenia (44% vs 14%) and neutropenia (56% vs 27%).
Conclusion: Oxaliplatin/docetaxel has activity in metastatic non-small cell lung cancer, but it seems to be inferior to cisplatin/docetaxel.

• 出版日期2013-2-5